Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Eli Lilly

Trump's Gold Tariffs Shake Markets, Eli Lilly Plunges, Oil Dips On US-Russia Deal, Jobs Miss Fuels Recession Fears — This Week In Economy

The past week has been a rollercoaster ride for the financial markets. From President Donald Trump‘s surprising tariffs on gold to Eli Lilly’s worst day in 25 years, the week was filled with unexpected turns. Let’s dive into the top stories that shaped the week.

Benzinga

My Portfolio, Powered by AI: The Surprising Truth About Automated Investing

When it comes to investing, research is everything. But let’s be honest, it can also be time-consuming and overwhelming, especially if you have never invested...

Saving Advice

Eli Lilly's Orforglipron Data Is Not Disastrous: Analyst

Eli Lilly and Co (NYSE:LLY) released underwhelming data from a Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity?

Weight loss drug goliath Eli Lilly just tanked despite posting impressive Q2 results. See what drove the decline and whether the market reaction is overdone.

MarketBeat

S&P Futures Gain as Investors Weigh Trump’s Fed Governor Pick; Gold Futures Jump on Tariff Report

September S&P 500 E-Mini futures (ESU25) are trending up +0.32% this morning, capping a week dominated by tariff and geopolitical developments, as well as a wave of earnings, with investors weighing U.S. President Donald Trump’s efforts to tighten his grip on the Federal Reserve.

Barchart

The Trade Desk, SoundHound AI, Eli Lilly, Block And CrowdStrike: Why These 5 Stocks Are On Investors' Radars Today

The U.S. stock market saw a mixed performance today, with the Nasdaq gaining over 70 points, reflecting a 0.35% increase to 21,242.70. Meanwhile, the SP 500 fell by 0.08% to 6,340, and the Dow Jones Industrial Average experienced a decline of 0.5% to settle at 43,968.64.

Benzinga

Stocks Close Mixed after Higher Bond Yields and Tariff News

The S&P 500 Index ($SPX ) (SPY ) Thursday closed down -0.08%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.51%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.32%. September E-mini S&P futures (ESU25 ) fell -0.04%, and September E-mini Nasdaq futures (NQU25...

Barchart

Read news from The Economist, FT, and more,
with one subscription

Stocks Swing Lower as Eli Lilly, Fortinet Spiral: Stock Market Today

The main indexes finished well off their session highs after a disappointing batch of corporate earnings reports.

Kiplinger

Daily pill helps patients lose 12% of body weight in early trial

Results of study suggest orforglipron could be a simpler, cheaper alternative to injections

The Guardian - UK

Eli Lilly Co. Q2 FY2025 Earnings Transcript

Eli Lilly Co. (NYSE:LLY) reported its second-quarter 2025 financial results ahead of the opening bell on Thursday.

Benzinga

Apple Jumps, Eli Lilly Crashes On Worst Day In 25 Years: What's Moving Markets Thursday?

U.S. equities slipped midday Thursday as corporate earnings and fresh tariff announcements from President Donald Trump drove divergent moves in heavyweight names.

Benzinga

This Blue-Chip Stock Is Cooking Up a Major Growth Catalyst

Eli Lilly is poised for a major boost as new data shows its diabetes drug Mounjaro offers heart health benefits, potentially making it the top choice for patients with Type 2 diabetes.

Barchart

Stocks Turn Mixed After an Early Rally

The S&P 500 Index ($SPX ) (SPY ) today is down -0.04%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.53%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.44%. September E-mini S&P futures (ESU25 ) are down -0.04%, and September E-mini Nasdaq futures...

Barchart

Eli Lilly will seek approval for experimental weight loss pill after promising study

Study participants lost an average of 12.4 per cent of their body weight over 72 weeks.

Euronews

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Viking Therapeutics Inc. (NASDAQ:VKTX), and Structure Therapeutics Inc. (NASDAQ:GPCR) are trading higher.

The Independent UK

‘Shock’ as study reveals how weight-loss pill stacks up against injections

Shares in a pharmaceutical company plummeted after the results were made public

Benzinga

Eli Lilly's Closely Watched Obesity Pill Orforglipron Shows Around 12% Weight Loss But Trails Novo Nordisk (UPDATED)

Eli Lilly and Co. (NYSE:LLY) stock plunged on Thursday after the company released topline data from the Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist.

Benzinga

Eli Lilly, ConocoPhillips And 3 Stocks To Watch Heading Into Thursday

With U.S. stock futures trading higher this morning on Thursday, some of the stocks that may grab investor focus today are as follows:

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

How To Earn $500 A Month From Eli Lilly Stock Ahead Of Q2 Earnings

Eli Lilly and Company (NYSE:LLY) will release earnings results for the second quarter before the opening bell on Thursday, Aug. 7.

Barchart

Is Wall Street Bullish or Bearish on Eli Lilly Stock?

Eli Lilly shares have underperformed the broader market over the past year, but Wall Street analysts remain firmly bullish in the company’s long-term growth prospects.

Benzinga

Trump Threatens Pharma With Potential 250% Tariffs In 18 Months: 'We Want Pharmaceuticals Made In Our Country'

President Donald Trump has indicated the possibility of imposing tariffs on imported pharmaceuticals that could rise up to 250%, indicating the highest rate he has proposed so far.

Barchart

Is Novo Nordisk Stock a Buy, Sell, or Hold Before Q2 Earnings?

With Novo Nordisk shedding double digits following its latest guidance cut, is this a chance to buy the dip or a warning sign of deeper trouble ahead?

MarketBeat

Novo Nordisk Stock Sinks—But Is a Bottom Finally In?

Novo Nordisk stock is down over 43% in 2025 as investors weigh weak guidance, GLP-1 competition, and the potential for a rebound after earnings

Benzinga

Hims & Hers Health Stock Plunges Over 13% In Tuesday Pre-Market: What's Going On?

Hims Hers Health Inc. (NYSE:HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported second-quarter revenue on Monday that missed Wall Street expectations.

The Independent UK

Weight loss drugs could soon be used to treat these seven other health conditions

Eli Lilly and Novo Nordisk are actively exploring other medical uses for their GLP-1 drugs, and have already seen some success

1 … 11 12 13 14

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.